Skip to main content
Clinical Trials/NCT02132806
NCT02132806UnknownNot Applicable

Piezosurgery in the Treatment of Class II Furcation Involvement

Matteo Visintin1 site in 1 country30 target enrollmentStarted: March 1, 2014Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
Horizontal probing depth (PH)

Study Overview

Brief Summary

The purpose of this study is to evaluate the effectiveness of piezosurgery in the treatment of class II furcation involvement using biomaterials and new surgical techniques

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •previous subgingival instrumentation with adequate plaque control (FMPS < 20%) and bleeding on probing (FMBS < 20%).
  • •one or more mandibular molar with buccal class-II furcation involvement

Exclusion Criteria

  • •diabetes mellitus
  • •pregnancy and lactation period
  • •subjects smoking > 10 cigarettes/day were excluded
  • •subjects in chronically treatment with calcium antagonist, immunosuppressive drugs and Antiepileptic Drugs

Arms & Interventions

OFD with piezosurgery+biomaterial

Experimental

Open flap debridement with Piezosurgery with biomaterial mp3

Intervention: Piezosurgery with biomaterial mp3 (Procedure)

OFD with piezosurgery+mp3+bracket

Experimental

Open flap debridement with Piezosurgery with biomaterial mp3 + bracket

Intervention: Piezosurgery with biomaterial mp3 + bracket (Procedure)

OFD with piezosurgery

Experimental

Open flap debridement with Piezosurgery

Intervention: Piezosurgery (Procedure)

Outcomes

Primary Outcomes

Horizontal probing depth (PH)

Time Frame: 180 days

horizontal probing depth

Secondary Outcomes

  • Pocket probing depth (PPD)(180 days)
  • Furcation closure (FC)(180 days)
  • Plaque index (PI)(180 days)
  • Bleeding on probing (BoP)(180 days)
  • Clinical attachment level (CAL)(180 days)

Investigators

Sponsor
Matteo Visintin
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Matteo Visintin

Student

University of Trieste

Study Sites (1)

Loading locations...

Similar Trials